middle.news
Cleo Advances Ovarian Cancer Test Toward FDA Evidence Milestone
9:14am on Thursday 10th of September, 2026 AEST
•
Healthcare
Read Story
Cleo Advances Ovarian Cancer Test Toward FDA Evidence Milestone
9:14am on Thursday 10th of September, 2026 AEST
Key Points
Asuragen engaged for pivotal U.S. clinical validation
Approximately 1,470 samples across three studies
Program will measure sensitivity, specificity, PPV and NPV
Bio-Techne relationship now spans kits, platform and clinical testing
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cleo Diagnostics (ASX:COV)
OPEN ARTICLE